Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer

Published:2023-06 Issue: Volume:62 Page:102686
ISSN:2213-2317
Container-title:Redox Biology
language:en
Short-container-title:Redox Biology

Author:

Chen Wei-Yu,Thuy Dung Phan Vu,Yeh Hsiu-Lien,Chen Wei-Hao,Jiang Kuo-Ching,Li Han-Ru,Chen Zi-Qing,Hsiao Michael,Huang Jiaoti,Wen Yu-Ching,Liu Yen-Nien^ORCID

Publisher

Elsevier BV

Subject

Organic Chemistry,Biochemistry,Clinical Biochemistry

Reference66 articles.

1. Cancer statistics, 2020, CA;Siegel;Cancer J. Clinic.,2020

2. Development and prevalence of castration-resistant prostate cancer subtypes;Vellky;Neoplasia,2020

3. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses;Li;Nat. Commun.,2018

4. Mechanisms of therapeutic resistance in prostate cancer;Nakazawa;Curr. Oncol. Rep.,2017

5. org, Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Parker;Ann. Oncol.,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship;Bioorganic Chemistry;2023-12

2. The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues;2023-09-29

3. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer;International Journal of Molecular Sciences;2023-09-05

4. The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer;Cancers;2023-06-08